No crisp upper hand in CRISPR
What the most recent CRISPR ruling means for companies looking to access the IP
While the most recent ruling in the ongoing CRISPR IP battle maintained the Broad Institute’s dominant patent position in the U.S., University of California Berkeley’s dominant position in Europe, coupled with the looming possibility of additional interference cases, means that companies may still have to seek licenses from both parties to create global therapeutics.
On Sept. 10, the U.S. Court of Appeals for the Federal Circuit (CAFC) upheld a no interference-in-fact decision made by the Patent Trial and Appeal Board (PTAB) last year in a case pitting the Regents of the University of California against the Broad Institute of MIT and Harvard. ...